Cytolytic activity and immunological responses of TKD activated natural killer cells in patients with colorectal carcinoma and non-small cell lung cancer.

Trial Profile

Cytolytic activity and immunological responses of TKD activated natural killer cells in patients with colorectal carcinoma and non-small cell lung cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2016

At a glance

  • Drugs TKD-activated natural killer cells (Primary) ; Interleukin-2
  • Indications Carcinoma; Colorectal cancer; Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 14 Jan 2016 New trial record
    • 01 Jun 2004 Results published in the Internet Document
    • 01 Sep 2002 Recruitment completed according to results published in the Internet Document.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top